Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Shin Nippon Biomedical Laboratories Ltd (2395)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,535.0 -7.0    -0.45%
02/05 - Closed. Currency in JPY ( Disclaimer )
  • Volume: 196,700
  • Bid/Ask: 1,535.0 / 1,542.0
  • Day's Range: 1,521.0 - 1,546.0
Type:  Equity
Market:  Japan
ISIN:  JP3379950003 
Shin Nippon Biomed Lab 1,535.0 -7.0 -0.45%

2395 Financial Summary

 
A brief financial summary of Shin Nippon Biomedical Laboratories Ltd as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Shin Nippon Biomedical Laboratories, Ltd. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported sales was JPY 25,090.9 million compared to JPY 17,748.48 million a year ago. Net income was JPY 6,060.06 million compared to JPY 7,127.63 million a year ago. Basic earnings per share from continuing operations was JPY 145.56 compared to JPY 171.2 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

2395 Income Statement

Gross margin TTM 52.19%
Operating margin TTM 14.97%
Net Profit margin TTM 20.61%
Return on Investment TTM 6.65%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 6100.68 6080 5804 8719
Gross Profit 3184 3160 3193 4400
Operating Income 186.25 1123 1227 1461
Net Income 828 1593 1373 1709

2395 Balance Sheet

Quick Ratio MRQ 0.83
Current Ratio MRQ 1.5
LT Debt to Equity MRQ 61.09%
Total Debt to Equity MRQ 88.42%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 71371.71 68558 62615 57242
Total Liabilities 41118.73 36837 35879 30884
Total Equity 30252.98 31721 26736 26358

2395 Cash Flow Statement

Cash Flow/Share TTM 45.61
Revenue/Share TTM 641.41
Operating Cash Flow  0.00%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change in Cash
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2395 Comments

Write your thoughts about Shin Nippon Biomedical Laboratories Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email